Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 1.00 |
| ▸ | PPARG | P37231 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.80 |
| ▸ | MEN1 | O00255 | 3/20 | 0.80 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.80 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.80 |
| ▸ | PKM | P14618 | 1/20 | 0.80 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.80 |
| ▸ | MAPT | P10636 | 3/20 | 0.73 |
| ▸ | USP2 | O75604 | 1/20 | 0.73 |
| ▸ | LMNA | P02545 | 1/20 | 0.73 |
| ▸ | ELANE | P08246 | 1/20 | 0.73 |
| ▸ | FLT3 | P36888 | 2/20 | 0.67 |
| ▸ | POLB | P06746 | 2/20 | 0.67 |
| ▸ | NPC1 | O15118 | 1/20 | 0.67 |
| ▸ | KIT | P10721 | 1/20 | 0.67 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.67 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.67 |
| ▸ | RAB9A | P51151 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29449516 | 0.93 | ALDH1A1 (0.88) | ALDH1A1PPARGMAPK1CYP3A4MEN1 | |
| Nevadensin SCHEMBL2178589 | 0.92 | ALDH1A1 (0.85) | ALDH1A1PPARGMAPK1CYP3A4MEN1 | |
| Nevadensin SCHEMBL29155335 | 0.92 | ALDH1A1 (0.85) | ALDH1A1PPARGMAPK1CYP3A4MEN1 | |
| Xanthomicrol SCHEMBL6257160 | 0.91 | PPARG (1.00) | ALDH1A1PPARGMAPK1CYP3A4MEN1 | |
| SCHEMBL31237871 | 0.90 | ALDH1A1 (0.81) | ALDH1A1PPARGMAPK1CYP3A4MEN1 | |
| Tangeretin SCHEMBL23629519 | 0.89 | ALDH1A1 (1.00) | ALDH1A1PPARGMAPK1CYP3A4MEN1 | |
| Tangeretin SCHEMBL19740 | 0.89 | ALDH1A1 (1.00) | ALDH1A1PPARGMAPK1CYP3A4MEN1 | |
| Tangeretin SCHEMBL29549538 | 0.89 | ALDH1A1 (1.00) | ALDH1A1PPARGMAPK1CYP3A4MEN1 | |
| SCHEMBL26112503 | 0.88 | PPARG (0.81) | ALDH1A1PPARGMAPK1CYP3A4MEN1 | |
| Sideritiflavone SCHEMBL29973995 | 0.86 | PPARG (0.77) | ALDH1A1PPARGMAPK1CYP3A4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 164 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260115294-A1 | DERIVATIVES OF 5-HYDROXYLATED POLYMETHOXYFLAVONES WITH ENHANCED BIOAVAILABILITY FOR ORAL DELIVERY AND COMPOSITIONS THEREOF | DEEPSENSE BIOTECHNOLOGIES INC (US) | 2026-04-30 | — | — | US | claimed |
| CN-120009445-A | Detection method and kit for ageing process | 中国检验检疫科学研究院 | 2025-05-16 | — | — | CN | claimed |
| US-20250051551-A1 | IMPROVED POLYMER COMPOSITES | WARNER BABCOCK INSTITUTE FOR GREEN CHEMISTRY, LLC (US) | 2025-02-13 | — | — | US | claimed |
| CN-119074820-A | Polymethoxy flavone component enriched from pericarpium citri reticulatae, and enrichment method and application thereof | 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） | 2024-12-06 | — | — | CN | claimed |
| US-20240315965-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2024-09-26 | — | — | US | claimed |
| US-20230089351-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2023-03-23 | — | — | US | claimed |
| WO-2022182523-A1 | COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2022-09-01 | — | — | WO | claimed |
| WO-2022182527-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2022-09-01 | — | — | WO | claimed |
| CN-114146124-A | Application of phyllanthus emblica embryo polymethoxylated flavonoids compound in preparation of antioxidant | 中山大学 | 2022-03-08 | — | — | CN | claimed |
| CN-114053346-A | Application of phyllanthus emblica embryo polymethoxylated flavonoids compound in preparation of blood fat reducing product | 中山大学 | 2022-02-18 | — | — | CN | claimed |
| WO-2007024982-A2 | METHODS FOR MANAGING ADIPOCYTE FAT ACCUMULATION | WELLGEN, INC. (US) | 2007-03-01 | — | — | WO | claimed |
| US-20070042972-A1 | Compositions and methods for optimizing exercise recovery | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2007-02-22 | — | — | US | claimed |
| WO-2006127996-A2 | COMPOSITIONS AND METHODS FOR OPTIMIZING EXERCISE RECOVERY | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2006-11-30 | — | — | WO | claimed |
| US-20040152760-A1 | Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases | PROTAMED, INC. | 2004-08-05 | — | — | US | claimed |
| JP-2003532634-A | — | — | 2003-11-05 | — | — | JP | claimed |
| EP-1244435-A2 | POLYHYDROXYLATED AROMATIC COMPOUNDS FOR THE TREATMENT OF AMYLOIDOSIS AND $g(a)-SYNUCLEIN FIBRIL DISEASES | Proteotech Inc. (US) | 2002-10-02 | — | — | EP | claimed |
| US-20010047032-A1 | Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases | PROTAMED, INC. | 2001-11-29 | — | — | US | claimed |
| WO-2001049281-A2 | POLYHYDROXYLATED AROMATIC COMPOUNDS FOR THE TREATMENT OF AMYLOIDOSIS AND α-SYNUCLEIN FIBRIL DISEASES | PROTEOTECH, INC. (US) | 2001-07-12 | — | — | WO | claimed |
| EP-0605261-B1 | Use of a flavone derivative as taste modifier and a method of modifying taste | SAN EI GEN FFI INC (JP) | 1999-09-15 | — | — | EP | claimed |
| EP-0605261-A2 | A taste modifier and a method of modifying taste | SAN-EI GEN F.F.I., INC. (JP) | 1994-07-06 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070042972-A1 | Compositions and methods for optimizing exercise recovery | GYS1, PYGM, PRDX5 | ALDH1A1 3163/4885PPARG 178/4885MAPK1 1794/4885 |
| US-20230089351-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | FABP2, FABP4, GUSB | ALDH1A1 2722/4885PPARG 319/4885MAPK1 3646/4885 |
| US-20010047032-A1 | Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases | SNCA, PARK7, HTT | ALDH1A1 1370/4885PPARG 391/4885MAPK1 2917/4885 |
| US-20260115294-A1 | DERIVATIVES OF 5-HYDROXYLATED POLYMETHOXYFLAVONES WITH ENHANCED BIOAVAILABILITY FOR ORAL DELIVERY AND COMPOSITIONS THEREOF | PLIN3, PNLIP, FABP2 | ALDH1A1 2873/4885PPARG 210/4885MAPK1 2886/4885 |
| US-20040152760-A1 | Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases | SNCA, PARK7, HTT | ALDH1A1 1370/4885PPARG 391/4885MAPK1 2917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.